The aim of this study was to compare the efficacy of sildenafil and continuous positive airway pressure (CPAP) in men with erectile dysfunction (ED) and obstructive sleep apnea syndrome (OSAS). In all, 30 men were randomly treated for 12 weeks either with sildenafil 100 mg before intercourse (15 men) or CPAP during night time sleep (15 men). Under sildenafil, 97/180 (53.9%) of attempted intercourses were successful compared to 33/138 (23.9%) under CPAP. The mean IIEF (erectile function domain score) was 12.9 and 9.3 after sildenafil and CPAP treatment, respectively (P ¼ 0.007), compared to 7.9 and 7 at baseline. In all, 53.3% of patients were satisfied with sildenafil and 20% with CPAP for ED treatment (P ¼ 0.058). Although sildenafil was superior to CPAP, comorbidities and OSAS per se possibly resulted in a lower effectiveness of sildenafil compared to that in the general population of ED men. While about half of the patients were not satisfied even with the more effective treatment, we conclude that a combination of the two therapeutic tools or a different therapeutic mode should be studied further.
Introduction
Obstructive sleep apnea syndrome (OSAS) is a common disorder characterized by repetitive, complete or partial pharyngeal collapse during sleep, which causes a cessation or reduction of breathing with consequent blood oxygen desaturation and sleep fragmentation. Among its sequelae, erectile dysfunction (ED) has been reported as an early sign of nerve involvement. Fanfulla et al 1 suggested that the impairment of sacral segment function in OSAS patients is related to the development of signs of male ED. Although the etiologic association between OSAS and ED is controversial, sexual problems are common among men with sleep apnea/hypopnea. An incidence of 48% of sexual problems has been reported among men aged 25-65 y with sleep apnea. 2 On the other hand, a high rate of sleep disorders ranging from 44 to 61% was detected during nocturnal penile tumescence studies in men with ED. [3] [4] [5] ED represents a model of endothelial dysfunction, and is often related with comorbidities such as diabetes mellitus, atherosclerosis, hypertension and coronary artery disease. 6 Besides diabetes, other conditions have been reported as long-term complications of OSAS, and a dearth of nitric oxide (NO) may contribute to their development. [7] [8] [9] NO and obstructive apnea are inseparable conditions. 10 Thus, the impairment of NO vasoprotective function may explain the association between OSAS and ED and may also indicate optimal therapeutic management.
Nasal continuous positive air pressure (CPAP) is the treatment of choice for obstructive sleep apnea and its sequelae. 11 Its efficacy has also been studied in the treatment of associated ED. 12 The armamentarium of oral ED medications 5 y ago was enriched with sildenafil citrate, a phosphodiesterase type 5 inhibitor. Sildenafil, irrespectively of the underlying pathology, influences local regulatory mechanisms and enhances erection by potentiating the smooth muscle-relaxing effects of NO on resistance vessels and trabecular smooth musculature of corpus cavernosum. In this study, we compared the efficacy of CPAP and sildenafil in the management of ED in men with OSAS.
Patients and methods
This prospective, randomized unsponsored trial included 30 consecutive men with ED who had been referred to the outpatient clinic for sleep disorders and proved to suffer from OSAS. All patients were monitored two consecutive nights for diagnosis and one additional night for therapeutic titration by a polygraph data recording system for the following parameters: electroencephalogram, electro-oculogram, chin, intercostal and bilateral anterior tibialis electromyography, electrocardiogram, nasal and buccal thermistors to assess air exchange, tachograph for beat-to-beat heart rate and ear oxymetry for blood oxygen saturation. Sleep stages and events were scored manually according to standard criteria. 13 Apnea was defined as the complete cessation of airflow for at least 10 s and hypopnea as the reduction in airflow of at least 50% for 10 or more seconds. The number of apnea and hypopnea episodes per hour of sleep is called 'apnea/hypopnea index' (or respiratory distress index). An index of at least six respiratory events (apneas and hypopneas) per hour of sleep was required for the diagnosis of OSAS and inclusion in this study.
Patients with OSAS were asked to answer to questions 3 (Over the past 4 weeks, how often were you able to penetrate your partner?) and 4 (Over the past 4 weeks, how often were you able to maintain your erection after you had penetrated your partner?) of IIEF.
14 When the score was r4, they were referred for andrologic evaluation if they agreed to. Within a 4-week baseline period a detailed history was taken, the men were physically examined and underwent real-time rigidity measurement, laboratory biochemical and hormonal tests, and finally completed an IIEF questionnaire form. Real-time rigidity was evaluated by Rigiscan (Dacomed, Minneapolis, MN, USA) for a period of 30 min after the injection of 10 mg of prostaglandin E1 with simultaneous visual stimulation. An objectively satisfactory response was considered if the circumference increased by 30 mm or more and a rigidity of 70% or more was obtained for at least 10 min for both.
Patients were excluded if they had a deformity in external genitals, if they took nitrates, if they were already in a treatment for ED, if they had any hormonal deficiency and if they did not have a stable relation for at least 6 months. Men who agreed to be treated were randomly allocated, by a computer generation table of random numbers, to receive sildenafil 100 mg on demand 1 h prior to intercourse (15) or to be treated with CPAP at home during night time sleep (15) . The therapeutic CPAP levels were determined during the full night of therapeutic titration. The treatment period lasted 12 weeks. The purpose of the management was thoroughly explained to the couples. They were encouraged to attempt sexual intercourse and were instructed for manual stimulation during foreplay. They were also asked to report immediately after intercourse on the success of the attempt in a standardized event-log (SEP-Sexual Encounter Profile). Men were thoroughly instructed on how to take the medication or use the device and they were ordered to refer immediately any adverse effect. They were regularly assessed every 4 weeks and finally evaluated in detail at the end of treatment period, when they completed an IIEF form and replied with 'Yes' or 'No' to the question 'Were you satisfied with this treatment for ED?' Patients continued to receive medications for concomitant diseases throughout the study.
Primary outcomes of the study were the percentage of successful for intercourse attempts, the IIEF score and the satisfaction with treatment for ED. Secondary outcomes were the scores for IIEF domains. Statistical analysis of continuous outcomes was performed by unpaired Student's t-test. The dichotomous outcome was assessed by a w 2 -Yates' corrected test. All P-values were two-tailed, and a result was considered to be statistically significant if it was less than 0.05.
Results
In both groups patients were matched for age, severity of OSAS and ED duration. The baseline characteristics are shown in Table 1 . They were also matched for IIEF total and domain scores as shown in Table 2 (pre-T). Comorbidities such as diabetes mellitus, atherosclerosis, hyperlipidemia, coronary artery disease and hypertension were evenly distributed in both groups. In each group, 11 men (73%) had one or more concomitant diseases; in the CPAP arm, the distribution of patients with one, two or three comorbidities was in 53.3, 6.6 and 13.3% of patients, respectively. Accordingly, in the sildenafil arm the percentages were 33.3, 33.3 and 6.6%, respectively. A total of 11 men treated with CPAP and 12 men treated with sildenafil were heavy smokers. Except for two men treated with sildenafil and one treated with CPAP, all subjects were considered overweight. Real-time rigidity monitoring was abnormal in nine men treated with Treatment of ED in obstructive sleep apnea P Perimenis et al CPAP and in seven men treated with sildenafil (P ¼ 0.5)
The 15 men treated with CPAP attempted 138 intercourses accounting for a mean of 9.2 attempts per patient during the treatment period. Of them, 33 (23.9%) were successful for intercourse. Men treated with sildenafil attempted more intercourses and recorded a significantly higher rate of successful attempts compared to men treated with CPAP. They recorded 180 attempts for intercourse with a rate of 12 attempts per patient (P ¼ 0.005) and, of them, 97 (53.9%) were successful (P ¼ 0.001). The profile of the attempts for intercourse in two groups is depicted in Figure 1 .
IIEF total and all domain scores were increased in both groups compared to baseline. Post-treatment IIEF total and all domain scores, except for that of sexual desire domain, were significantly higher in men treated with sildenafil than in men treated with CPAP (Table 2, post T). At the end of study, three of the 15 men (20%) were satisfied with CPAP for treatment of ED, while eight of the 15 men (53.3%) were satisfied with sildenafil, respectively. This difference in satisfaction with treatment of ED was not statistically significant (0.13).
The two treatment modes were well tolerated and all patients completed the therapeutic protocol. Nasal dryness was the more frequently reported complaint with CPAP treatment. Some episodes of transient flushing and mild headache reported in the sildenafil arm were unimportant, and no patient required any specific treatment.
Discussion
In this study, we assessed and compared the effectiveness of CPAP and sildenafil in a homogeneous group of patients with OSAS and ED. Hypoxic episodes are common in sleep apnea and in coordination with the arousals-related, endapneic hyperadrenergic reactions may be responsible for OSAS-associated complications, including ED.
1 The key event is possibly the reduction in circulating NO levels, which increases platelet aggregation and vasoconstriction and impairs function of the vascular endothelial cells. [15] [16] [17] [18] [19] Oxygen therapy has been reported to improve potency in men with obstructive pulmonary diseases. Aasebo et al 20 reported a 42% reversal of ED in men with chronic obstructive pulmonary disease receiving a 1-month oxygen therapy. Short-term nasal CPAP also improved the impaired nocturnal penile tumescence in one-third of patients in a study of men with OSAS and ED. 12 By using successful for intercourse attempts as a primary outcome in our study, we observed a 25% success rate in sexual attempts of men under CPAP therapy. The effectiveness of CPAP may be due to an increase of NO circulating levels and the consequent improvement of endothelial cell function. 16, 18, 19 Sildenafil was more effective than CPAP in these men in as much as 54% of the attempts for intercourse were successful, and IIEF total and almost all domain scores improved significantly compared to those in men treated with CPAP. The difference in effectiveness is possibly due to the mode of action of sildenafil, which acts peripherally, facilitating the erectile response by direct smooth muscle relaxation in the penile arteries and erectile tissue. 21 The higher number of intercourse attempts by men treated with sildenafil may be explained by the higher effectiveness of sildenafil in the treatment of ED. Moreover, the nature of the oral sildenafil therapy allows for more spontaneous attempts for intercourse in a couple, when compared to the use of CPAP.
The rate of successful for intercourse attempts achieved with sildenafil in patients with OSAS is lower than the one reported in the general population of similar age men seeking treatment for ED, 21, 22 as well as in a specific ED male population. 23 It seems probable that except for the high incidence of comorbidities that represent true risk factors for ED among the studied men, OSAS per se decreases 24 Moreover, one should take into account that in the sildenafil arm no CPAP was used for 3 months. Although the severity of OSAS in this group was mild (as suggested by the mean apnea/hypopnea indices), the persistency of the original OSAS symptoms may simply have negatively affected the overall quality of life in these patients, not allowing sildenafil to work better.
The efficacy of the two treatment modes in our study is reflected at the patients' satisfaction with treatment for ED. Although sildenafil proved to be a more effective treatment for ED in this study, approximately half of the patients were not satisfied with this treatment. In the case of CPAP dissatisfaction reached 80%. It should be noted, however, that satisfaction issues should be best assessed in a blinded fashion, in order to exclude psychological bias on different treatment arms. This could not apply in this study due to the obviously different nature of the two treatment modalities. Thus, satisfaction results should be interpreted with caution.
Nevertheless, it seems likely that none of the studied therapeutic modes met the needs and expectations of all patients. We concur with the suggestion that the treatment of a complex and multidimensional psycho-neuro-vascular entity cannot be successfully achieved by a single agent for all cases. 25 One of the limitations of this study (apart from small numbers) is the fact that our patients suffered from mild OSAS, as defined by a relative low mean apnea/hypopnea index at baseline. In more severe cases, however, sildenafil might be inadequate as a single agent for ED treatment. We are looking forward to studies that will further assess the efficacy of sildenafil and newer oral agents alone or in combination with CPAP in the treatment of ED in patients suffering from OSAS of different severity levels.
In conclusion, our data suggest that sildenafil was superior to CPAP in the treatment of ED in men with OSAS. The high rate of comorbidities in these patients and OSAS per se possibly result in a lower effectiveness of sildenafil compared to its effectiveness in the general population of men with ED. Owing to the high percentage of dissatisfaction with treatment, we conclude that a combination of the two therapeutic tools or a different therapeutic mode should be studied further. Treatment of ED in obstructive sleep apnea P Perimenis et al
